JPM: Aridis CEO Truong on why the pandemic hasn't bolstered antibiotics R&D and what needs to change
The COVID-19 pandemic has spurred enormous interest and innovation in vaccines, antivirals and anti-infective drugs and for obvious reasons. There’s another area that might have been buoyed by the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback